Barclays analyst Emily Field raised the firm’s price target on Novartis (NVS) to CHF 90 from CHF 85 and keeps an Underweight rating on the shares.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis AG Earnings Call Highlights Strong Growth and Strategic Challenges
- Navigating Risks: Novartis’s Strategic Challenges in Expanding Innovative Medicines Portfolio
- Novartis AG Reports Strong Sales Growth and Innovation
- Ionis ‘remains confident in pelacarsen’ after Novartis update on Phase 3 timing
- Morning Movers: Apple and Exxon higher following quarterly earnings